€0.66
Your prediction
Onconova Therapeutics Inc Stock
Pros and Cons of Onconova Therapeutics Inc in the next few years
Pros
Cons
Performance of Onconova Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Onconova Therapeutics Inc | -3.820% | - | - | - | - | - | - |
| Beximco Pharmaceuticals Ltd. GDR | - | 0.000% | -3.670% | -16.000% | -4.545% | -57.360% | -22.222% |
| Cellectar BioSciences Inc. | -4.640% | -7.362% | -5.031% | 139.683% | 32.456% | -74.833% | - |
| Arca Biopharma | 0.670% | 3.448% | 91.693% | 61.725% | 92.926% | 7.143% | -94.709% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Onconova Therapeutics (ONTX) is a pharmaceutical company within the industry, and based on the financial data, it seems to have experienced some mixed performance in recent years. The company has witnessed fluctuations in its financial statements, with some improvements observed, while other areas continue to face challenges. A thorough analysis of the company's financials from the balance sheets, cash flow, and income statements can provide insights into its performance and potential future prospects.
Increased Gross Profit: The yearly gross profit for Onconova Therapeutics shows a slight but steady rise from $231,000 in 2020 to $226,000 in 2021 and 2022.
Decrease in Research and Development Expenses: The company has reported a significant decrease in its research and development expenses in recent years, from $16,898,000 in 2020 to $11,406,000 in 2022. This reduction in expenses could indicate effective cost management or a shift in the company's research focus, potentially leading to more funds for other business needs.
